IP Verse

Proteolytically Cleavable Fusion Proteins With High Molar Specific Activity - EP3564267

The patent EP3564267 was granted to CSL Behring on Mar 17, 2021. The application was originally filed on Jun 14, 2007 under application number EP19162362A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3564267

CSL BEHRING
Application Number
EP19162362A
Filing Date
Jun 14, 2007
Status
Granted And Under Opposition
Feb 12, 2021
Grant Date
Mar 17, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SWEDISH ORPHAN BIOVITRUMDec 17, 2021AWA SWEDENWITHDRAWN
SANOFIDec 16, 2021ZWICKERWITHDRAWN

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4784950
DESCRIPTIONWO0179271
DESCRIPTIONWO0204598
DESCRIPTIONWO03059935
DESCRIPTIONWO03068934
DESCRIPTIONWO2004081053
DESCRIPTIONWO2004101740
DESCRIPTIONWO2005001025
DESCRIPTIONWO2005024044
DESCRIPTIONWO9109125
OPPOSITIONEP1444986
OPPOSITIONWO2004101740
SEARCHEP1444986
SEARCHEP1816201
SEARCHWO2004021861
SEARCHWO2004101739
SEARCHWO2004101740
SEARCHWO9601653

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALEDORT L.M., J Thromb Haemost, (20040000), vol. 2, no. 10, pages 1700 - 1708-
DESCRIPTION- BEATTIE; DUGAICZYK, Gene, (19820000), vol. 20, pages 415 - 422-
DESCRIPTION- COOKE; DAVID, J. Clin. Invest., (19850000), vol. 76, pages 2420 - 2424-
DESCRIPTION- EWENSTEIN BM et al., "Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B", Transfusion, (20020000), vol. 42, pages 190 - 197-
DESCRIPTION- LICHENSTEIN et al., J. Biol. Chem., (19940000), vol. 269, pages 18149 - 18154-
DESCRIPTION- MOLLERUP et al., Biotechnol. Bioeng., (19950000), vol. 48, pages 501 - 505-
DESCRIPTION- SHEFFIELD W.P. et al., Br. J. Haematol., (20040000), vol. 126, pages 565 - 573-
DESCRIPTION- WASLEY LC et al., "PACE/Furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway", J. Biol. Chem., (19930000), vol. 268, pages 8458 - 8465-
DESCRIPTION- WHITE GC et al., Recombinant factor IX. Thromb Haemost., (19970000), vol. 78, pages 261 - 265-
OPPOSITION- Mccue, Et Al., "Manufacturing process used to produce long-acting recombinant factor viii Fc fusion protein", Biologicals, (20150101), vol. 43, doi:10.1016/j.biologicals.2015.05.012, pages 213 - 219, XP055662575
OPPOSITION- Driessler Frank, Et Al, "Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype", BLOOD COAGULATION & FIBRINOLYSIS, Lippincott Williams & Wilkins, US, US , (20171001), vol. 28, no. 7, doi:10.1097/MBC.0000000000000638, ISSN 0957-5235, pages 540 - 550, XP055875941
OPPOSITION- Sommer J. M., Et Al, "Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories", HAEMOPHILIA, BLACKWELL SCIENCE, OXFORD, GB, GB , (20140301), vol. 20, no. 2, doi:10.1111/hae.12296, ISSN 1351-8216, pages 294 - 300, XP055875943
OPPOSITION- R. T. Peters et al, "Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein", Journal of Thrombosis and Haemostasis, Blackwell Pub., c2003-, (20130127), vol. 11, no. 1, doi:10.1111/jth.12076, ISSN 15387933, pages 132 - 141, XP055092640
OPPOSITION- Garabet G. Toby et al, "Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice", PLOS ONE, Public Library of Science, (20160203), vol. 11, no. 2, doi:10.1371/journal.pone.0148255, page e0148255, XP055420974
SEARCH- SHEFFIELD W P ET AL, "Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits", BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, (200408), vol. 126, no. 4, ISSN 0007-1048, pages 565 - 573, XP002395198 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents